FDA-cleared profile

AVIEW CAC

Coreline Soft Co., Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Provides quantitative coronary-plaque analysis using Agatston scoring, RCA/LCA segmentation, and calcium-score, gender, and age percentile risk stratification.

Clinical role
Quantitative analysis of calcified coronary plaque on non-contrast/non-gated chest CT: calculates the Agatston score while segmenting and evaluating the right and left coronary arteries, and provides percentile-based risk stratification by calcium score, gender, and age.
Images and patients
CT/CTA · Heart and coronary arteries
Key limitation
Keep in mind: Other CT manufacturers were not validated or recommended.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Provides quantitative coronary-plaque analysis using Agatston scoring, RCA/LCA segmentation, and calcium-score, gender, and age percentile risk stratification.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart and coronary arteries Input: Existing DICOM 3.0 non-contrast, non-gated chest CT from specified GE or GE-subsidiary acquisitions in adults over 40 years.
  • Who uses it?Intended users: Healthcare professionals, including radiologists and cardiologists.
  • What does the software produce?Output: Agatston score, RCA/LCA evaluation, and percentile risk categories.
  • What is its most important limitation?Key limitation: Other CT manufacturers were not validated or recommended.

Clinical takeaway. Clinical role: Provides quantitative coronary-plaque analysis using Agatston scoring, RCA/LCA segmentation, and calcium-score, gender, and age percentile risk stratification.

Evidence takeaway. Evidence from the reviewed source record: No clinical study was necessary; nonclinical testing used 150 gated and 150 non-gated cases, with ICC versus ground truth of 0.896 total, 0.927 LCA, and 0.840 RCA.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Provides quantitative coronary-plaque analysis using Agatston scoring, RCA/LCA segmentation, and calcium-score, gender, and age percentile risk stratification.
  • Exact FDA submission
  • Checked 2026-09-15

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Quantitative analysis of calcified coronary plaque on non-contrast/non-gated chest CT: calculates the Agatston score while segmenting and evaluating the right and left coronary arteries, and provides percentile-based risk stratification by calcium score, gender, and age.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "AVIEW CAC provides quantitative analysis of calcified plaques in the coronary arteries using non-contrast/non-gated Chest CT scans." … "It enables the calculation of the Agatston score for coronary artery calcification, segmenting and evaluating the right coronary artery and left coronary artery.". Read from the exact FDA decision document on 2026-11-14.

Required input
Existing DICOM 3.0 non-contrast, non-gated chest CT from specified GE or GE-subsidiary acquisitions in adults over 40 years.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA input and compatibility scope.

Output and clinician action
Agatston score, RCA/LCA evaluation, and percentile risk categories.
  • Exact FDA submission
  • Checked 2026-09-15

FDA output description.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Healthcare professionals, including radiologists and cardiologists.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet user statement.

Limitations
Other CT manufacturers were not validated or recommended.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA compatibility boundary.

Evidence summary
No clinical study was necessary; nonclinical testing used 150 gated and 150 non-gated cases, with ICC versus ground truth of 0.896 total, 0.927 LCA, and 0.840 RCA.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet evidence summary.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
No clinical study was necessary; nonclinical testing used 150 gated and 150 non-gated cases, with ICC versus ground truth of 0.896 total, 0.927 LCA, and 0.840 RCA.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet evidence summary.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

AVIEW CAC regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K233211
  • Samplen=300
  • IndependenceIndependence not established

K233211

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233211. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Existing DICOM 3.0 non-contrast, non-gated chest CT from specified GE or GE-subsidiary acquisitions in adults over 40 years.

    Scope: Exact FDA submission. Exact FDA input and compatibility scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-15 · FDA K233211: AVIEW CAC

  2. Routing

    Source context, not route validation: The exact FDA package describes AVIEW CAC showing images from various storage devices using DICOM 3.0, receiving DICOM data from CT, conducting DICOM communication with PACS, importing DICOM files directly, and saving by using an export function. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "It shows images taken with the interface from various storage devices using DICOM 3.0, the digital image and communication standard in medicine." … "This receives DICOM data from CT by DICOM communication Conducts". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA K233211: AVIEW CAC

  3. AI processing

    Source context, not route validation: On-premises deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Deployment mode explicitly reported in the exact-submission ACR model card; hosting region and current commercial configuration still require vendor confirmation.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-01 · AVIEW CAC model card (K233211)

  4. Returned objects

    Source context, not route validation: Agatston score, RCA/LCA evaluation, and percentile risk categories.

    Scope: Exact FDA submission. FDA output description.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-15 · FDA K233211: AVIEW CAC

  5. Viewer/worklist/report

    Unresolved route: Agatston score, RCA/LCA evaluation, and percentile risk categories.

    Scope: Exact FDA submission. FDA output description.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-15 · FDA K233211: AVIEW CAC

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
On-premises deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Deployment mode explicitly reported in the exact-submission ACR model card; hosting region and current commercial configuration still require vendor confirmation.

Integration
The exact FDA package describes AVIEW CAC showing images from various storage devices using DICOM 3.0, receiving DICOM data from CT, conducting DICOM communication with PACS, importing DICOM files directly, and saving by using an export function. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "It shows images taken with the interface from various storage devices using DICOM 3.0, the digital image and communication standard in medicine." … "This receives DICOM data from CT by DICOM communication Conducts". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Deployment model

On-premises deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.

exact submission · checked 2026-09-01

Supported acquisition environment

Scanner manufacturers: GE

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for AVIEW CAC; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K233211
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA non-contrast chest CT normalized to the controlled CT/CTA bucket; CTA is not implied.

Anatomy
Heart and coronary arteries
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA anatomy scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-03-29
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K233211 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K233211: AVIEW CAC

    U.S. Food and Drug Administration - Published 2024-03-29 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, integration

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. AVIEW CAC model card (K233211)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, deployment, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K233211

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K233211 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K230112

CAC Software

Imbio, Inc.

Authorized purpose: Provides non-invasive post-processing to quantify possible coronary calcifications and output Agatston score, arterial age, mass, and volume.

Modality
CT/CTA
Anatomy
Heart and coronary arteries
Decision
2023-06-13
FDA-cleared K241440

HealthCCSng

Nano-X AI Ltd.

Authorized purpose: Non-invasive post-processing of routine non-gated, non-contrast CT studies containing the entire heart in adults aged 30 to 85 to evaluate coronary calcified plaque and estimate coronary calcium score and category.

Modality
CT/CTA
Anatomy
Heart and coronary arteries
Decision
2024-08-19
FDA-cleared K231631

BriefCase-Quantification

Aidoc Medical, Ltd.

Authorized purpose: Four-category coronary artery calcification (CAC) assessment of plaques on non-cardiac-gated, non-contrast CT images that include the heart; preview images are informational and the result is not for stand-alone clinical decision-making.

Modality
CT/CTA
Anatomy
Heart and coronary arteries
Decision
2023-11-28
FDA-cleared K201034

Syngo.CT CaScoring

Siemens Medical Solutions USA, Inc.

Authorized purpose: syngo.CT CaScoring analyzes noncontrast standard- or low-dose cardiac CT, marks calcified coronary lesions, allocates them to the right coronary, left main, left anterior descending, or circumflex artery, and calculates artery and total Agatston-equivalent, mass, and volume scores.

Modality
CT/CTA
Anatomy
Heart and coronary arteries
Decision
2020-05-14

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history